1. Home
  2. QXO vs NRIX Comparison

QXO vs NRIX Comparison

Compare QXO & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QXO
  • NRIX
  • Stock Information
  • Founded
  • QXO 1988
  • NRIX 2009
  • Country
  • QXO United States
  • NRIX United States
  • Employees
  • QXO N/A
  • NRIX N/A
  • Industry
  • QXO EDP Services
  • NRIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • QXO Technology
  • NRIX Health Care
  • Exchange
  • QXO Nasdaq
  • NRIX Nasdaq
  • Market Cap
  • QXO 6.0B
  • NRIX 1.3B
  • IPO Year
  • QXO N/A
  • NRIX 2020
  • Fundamental
  • Price
  • QXO $14.19
  • NRIX $25.44
  • Analyst Decision
  • QXO
  • NRIX Strong Buy
  • Analyst Count
  • QXO 0
  • NRIX 13
  • Target Price
  • QXO N/A
  • NRIX $26.92
  • AVG Volume (30 Days)
  • QXO 3.2M
  • NRIX 469.4K
  • Earning Date
  • QXO 11-12-2024
  • NRIX 10-10-2024
  • Dividend Yield
  • QXO N/A
  • NRIX N/A
  • EPS Growth
  • QXO N/A
  • NRIX N/A
  • EPS
  • QXO N/A
  • NRIX N/A
  • Revenue
  • QXO $57,106,941.00
  • NRIX $62,303,000.00
  • Revenue This Year
  • QXO N/A
  • NRIX N/A
  • Revenue Next Year
  • QXO N/A
  • NRIX $9.92
  • P/E Ratio
  • QXO N/A
  • NRIX N/A
  • Revenue Growth
  • QXO 14.88
  • NRIX 2.25
  • 52 Week Low
  • QXO $10.61
  • NRIX $4.22
  • 52 Week High
  • QXO $290.00
  • NRIX $26.12
  • Technical
  • Relative Strength Index (RSI)
  • QXO 40.16
  • NRIX 61.59
  • Support Level
  • QXO $14.45
  • NRIX $23.40
  • Resistance Level
  • QXO $16.01
  • NRIX $25.82
  • Average True Range (ATR)
  • QXO 0.95
  • NRIX 1.18
  • MACD
  • QXO 1.86
  • NRIX -0.07
  • Stochastic Oscillator
  • QXO 56.79
  • NRIX 85.67

About QXO QXO Inc. Common Stock

QXO Inc provides technology solutions, primarily to clients in the manufacturing, distribution and service sectors. It provides consulting and professional services, specialized programming, training and technical support also offers solutions for accounting, financial reporting, enterprise resource planning, warehouse management systems, customer relationship management, business intelligence and other applications. Additionally, QXO develops and publishes its own proprietary software.

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Share on Social Networks: